Proof-of-Concept: Human FAP-targeting Antibodies as Infarction Prevention Medications

• Forschungsstelle: INNOSUISSE
• Projektnummer: 14603.1;5 PFLS-LS
• Projekttitel Englisch: Human FAP-targeting Antibodies as Infarction Prevention Medications: Proof-of-Concept

Kurzbeschreibung (Deutsch)

Proof-of-Concept: Human FAP-targeting Antibodies as Infarction Prevention Medications

Kurzbeschreibung (Englisch)

Human FAP-targeting Antibodies as Infarction Prevention Medications: Proof-of-Concept

Abstract (Deutsch)

FlowMab is a human monoclonal antibody based medication designed to be administered to high-risk patients to reduce their acute and sub-acute risk of infarction. In this project, FlowMab drug candidates will be generated by Mabimmune for proof-of-concept testing in human biopsies and animal models at the Cardiovascular Research Group, Department of Surgical Research, University Hospital Zurich. This study is anticipated to result in proof-of-concept data of lead candidates necessary for: 1. Securing a partnership with a large industry partner for human clinical trials, 2. Improving FlowMab¿s risk profile for human trials, and 3. cueing the development of a companion diagnostic FAP blood test.

Abstract (Englisch)

FlowMab is a human monoclonal antibody based medication designed to be administered to high-risk patients to reduce their acute and sub-acute risk of infarction. In this project, FlowMab drug candidates will be generated by Mabimmune for proof-of-concept testing in human biopsies and animal models at the Cardiovascular Research Group, Department of Surgical Research, University Hospital Zurich. This study is anticipated to result in proof-of-concept data of lead candidates necessary for: 1. Securing a partnership with a large industry partner for human clinical trials, 2. Improving FlowMab¿s risk profile for human trials, and 3. cueing the development of a companion diagnostic FAP blood test.